Hepatocellular carcinoma as the Rose of Jericho:from the desert of sorafenib,to the blossoming of immunotherapy  

作　　者：Antonio D’Alessio Lorenza Rimassa 

机构地区：[1]Department of Surgery&Cancer,Imperial College London,Hammersmith Hospital,London,UK [2]Department of Biomedical Sciences,Humanitas University,Pieve Emanuele,Milan,Italy [3]Medical Oncology and Hematology Unit,Humanitas Cancer Center,IRCCS Humanitas Research Hospital,Rozzano,Milan,Italy

出　　处：《Hepatobiliary Surgery and Nutrition》2022年第3期485-488,共4页肝胆外科与营养（英文）

摘　　要：According to its etymology,the English word“liver”is related to the verb“to live”,and indeed there are few domains of oncology research as lively as liver cancer.The therapeutic landscape of hepatocellular carcinoma(HCC)has been rapidly changing over the last years,after the successful introduction of immune checkpoint inhibitors(ICIs)as standard of care for the treatment of unresectable or metastatic HCC(uHCC).Following more than a decade of tyrosine kinase inhibitors(TKIs)as the only available treatment for advanced HCC,in 2020 the results of the IMbrave150 trial radically changed the therapeutic algorithm(1,2).The combination of the anti-programmed death ligand 1(PD-L1)monoclonal antibody(mAb)atezolizumab and the anti-vascular endothelial growth factor(VEGF)mAb bevacizumab outperformed sorafenib in terms of overall survival(OS)and progression-free survival(PFS),meeting both its co-primary endpoints.The combination has been recognised as the new first-line standard of care by all major scientific societies,and it has been approved by regulatory agencies worldwide(3).

关 键 词：SORAFENIB IMMUNOTHERAPY MONOCLONAL 

分 类 号：R73[医药卫生—肿瘤]